BeiGene to helm Asian development of Zymeworks’ HER2 antibodies

Zymeworks Inc. (TSX:ZYME; NYSE:ZYME) granted BeiGene Ltd. (HKSE:6160; NASDAQ:BGNE) rights to HER2 antibodies ZW25 and ZW49,

Read the full 163 word article

User Sign In